GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial by R.C. Grant, K. Duan, R. Jackson, W. Greenhalf, E. Costello-Goldring, P. Ghaneh, C. Halloran, D. Palmer, T. Hackert, M. Büchler, S. Hutchinson, S. Ramotar, A. Dodd, J. Wilson, F. Notta, G. O’Kane, J. Knox, J. Neoptolemos, S. Gallinger, S.E. Fischer

“…ESMO Gastrointestinal Oncology…”
Get full text

The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival by L.M. Altus, J.C. Forster, J. Mercurio, M. Kitchener, N. Corsini, M. Nenke, T. Price, D. Patel, R. Chew, D. Moffat, S. Unger, G. Cehic

“…ESMO Gastrointestinal Oncology…”
Get full text

T-cell invigoration to cell-free DNA ratio associated with anti-PD-1 response in gastric or gastro-esophageal junction adenocarcinoma: VOYAGER trial by A. Makiyama, Q. Hu, T. Nagasaka, H. Katsuya, A. Nishioka, I. Yasufuku, T. Kashiwada, Y. Shinohara, S. Otsu, M. Shimokawa, H. Saeki, H. Baba, E. Oki

“…ESMO Gastrointestinal Oncology…”
Get full text

Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma by S. Shim, A.C. Larsen, L. Bæksgaard, P. Pfeiffer, M. Nordsmark, J.R. Sørensen, A.K. Motavaf, M. Ladekarl

“…ESMO Gastrointestinal Oncology…”
Get full text

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma by M. Tamba, K. Chin, H. Osumi, M. Ogura, S. Fukuoka, S. Udagawa, K. Shimozaki, K. Yoshino, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, A. Ooki

“…ESMO Gastrointestinal Oncology…”
Get full text

Controversies in upper GI oncology: role of radiotherapy in non-metastatic gastroesophageal adenocarcinoma by A. Petrillo, M. Verheij, T. Leong

“…ESMO Gastrointestinal Oncology…”
Get full text

Editorial Board

“…ESMO Gastrointestinal Oncology…”
Get full text

Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a post hoc analysis of JCOG1213 by H. Hirano, K. Hirata, Y. Honma, C. Morizane, N. Machida, K. Kato, T. Okusaka, N. Boku, S. Sekine, N. Hiraoka, J. Mizusawa, Y. Sano, Y. Shibuya, M. Takahashi, N. Fujimori, M. Nomura, Y. Doki, M. Ueno, T. Yoshikawa, H. Takeuchi

“…ESMO Gastrointestinal Oncology…”
Get full text

Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies by L. Weiss, D. Zhang, W.G. Kunz, S. Boeck, G. Curigliano, V. Subbiah, F. Lordick, T. Brummer, C.B. Westphalen, L. Boscolo Bielo

“…ESMO Gastrointestinal Oncology…”
Get full text

German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus—version 4.0 by M.P. Ebert, W. Fischbach, S. Hollerbach, J. Höppner, D. Lorenz, M. Stahl, M. Stuschke, O. Pech, U. Vanhoefer, C. Bruns, C. Ell, M. Follmann, U. Goerling, L. Grenacher, J. Haardt, A.H. Hölscher, R. Hummel, W.T. Knoefel, J. Körber, R. Langer, P. Lenz, F. Lordick, S. Lorenzen, A.G. Meining, J. Menzel, H.-J. Meyer, N.H. Nicolay, M. Nothacker, U. Nöthlings, H. Schmidberger, M. Schmidt, T. Seufferlein, P. Thuss-Patience, J. Trojan, A. Weimann, L. Klug, P. Lynen, T. Zhan, Q. Xiao, R. Porschen

“…ESMO Gastrointestinal Oncology…”
Get full text

Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study by A. Teixeira, T. Felismino, M.D. Donadio, G. Catani, A.L.M. da Silva, R. Weschenfelder, R.D. Peixoto, J.M. O’Connor, A.K. Coutinho, R.P. Riechelmann

“…ESMO Gastrointestinal Oncology…”
Get full text

Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma by J.W. Valle, G.K. Abou-Alfa, R.K. Kelley, M.A. Lowery, R.T. Shroff, Y. Bian, G. Saint-Hilary, H. Liu, Z. Teng, Z. Hua, C. Gliser, A. Vogel, M.M. Javle

“…ESMO Gastrointestinal Oncology…”
Get full text

Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer by H.F. Kennecke, J.A. Zell, H. Pham, V.V. Simianu, K. Herz, A. Kelley, J.C. Carmichael, H. Hochster, L.A. Kachnic

“…ESMO Gastrointestinal Oncology…”
Get full text

Multidisciplinary discussion in upper GI tumours: management of a patient with a locally advanced Siewert II gastroesophageal junctional adenocarcinoma by A. Petrillo, T. Fleitas-Kanonnikoff, M. Nilsson, T. Leong, H.W.M. van Laarhoven

“…ESMO Gastrointestinal Oncology…”
Get full text

Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy by M. Sugimori, A. Hirotani, H. Yamazaki, M. Oshi, K. Kawashima, H. Tsuchiya, Y. Kanemaru, Y. Suzuki, S. Onodera, H. Miwa, A. Nozaki, K. Sugimori, C. Kunisaki, M. Kudo, M. Morimoto, S. Maeda

“…ESMO Gastrointestinal Oncology…”
Get full text

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study by K. Nakanishi, N. Sugimoto, Y. Kodera, H. Kawakami, A. Makiyama, H. Konishi, S. Morita, Y. Narita, K. Minashi, M. Imano, R. Inamoto, T. Nishina, T. Kawakami, M. Hagiwara, H. Kume, K. Yamaguchi, W. Hashimoto, K. Muro

“…ESMO Gastrointestinal Oncology…”
Get full text

European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor’ by G. Folprecht, M. Morfouace, M. Collienne, R. Salazar, A. Stein, E. Elez, A.D. Wagner, D. Arnold, C.H. Kohne, M. Ducreux, F. Lordick, B. Borelli, A. Stevovic, T. Gorlia, E. Fontana, D. Aust, V. Golfinopoulos, M. Moehler, S. Tejpar

“…ESMO Gastrointestinal Oncology…”
Get full text

Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma by E. Scarlato, S. Casalino, L. Mendo, A. Sordo, V. De Vita, E. San Lorenzo, A. Quinzii, C. Zecchetto, G. Butturini, D. Melisi

“…ESMO Gastrointestinal Oncology…”
Get full text

Expanding the potential of antibody–drug conjugates in gastrointestinal malignancies: beyond HER2 targets by P. Ntellas, A. Athauda, K. Sugiyama, M.L. Le, V. Crespi, I. Chau

“…ESMO Gastrointestinal Oncology…”
Get full text

PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone by M. Sachdeva, J.J. Zhao, K.X. Zhu, D.T.W. Yap, N.Z.H. Wong, N.B. Kumarakulasinghe, J. Tey, R. Sundar

“…ESMO Gastrointestinal Oncology…”
Get full text